FDA Action Against Three Drug Firms For Violations

PUNE:  The Food and Drug Administration (FDA), Pune division, has acted against three drug stores for violation of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

The action was taken between April and October 2024 by the FDA, Pune division said the officials in the statement.

According to officials as per the DMR Act, advertisements for drugs for 54 diseases and disorders that fall under the schedule are prohibited. The schedule explicitly prohibits companies from promoting cures or making claims related to diseases and disorders. These firms were found selling drugs claiming to cure diabetes, arthritis and kidney ailments.

According to FDA officials, the Ayurvedic medicine worth Rs 36,500 has been seized under Section 3 of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 from New Maruti Ayurved, Chinchwad, for making an objectionable claim on the label of Amruth Noni D Plus regarding the treatment of diabetes. Besides, Ayurvedic medicine Orthojoint Oil worth Rs 5,027 was seized from Amit Medico, Sadashiv Peth, for making an objectionable claim about the cure of arthritis on the label, they said.

Furthermore, 16 sachets of Ayurvedic medicine worth ₹5,000 were seized from Mahalaxmi Ayurvedic, Pune, for making an objectionable claim about the cure of kidney stones on the label.

Girish Hukare, joint commissioner, FDA(Drug), Pune division, said, in one case of diabetic medicines we have filed a case and investigations in the other two incidents are ongoing.

“The DMR Act 1954 is implemented through the FDA to prevent people from self-medicating for various diseases. Medicines taken without consulting a doctor for serious illnesses can have harmful effects,” he said.

Hukare, further, said, the FDA regularly checks the labelling of medicines available in the market. If misleading claims are found, action is taken against those people.

“Advertisements on television and newspapers are also checked, and if objectionable advertisements are found, the concerned manufacturer is given a notice to stop the advertisement, and further action is initiated by the respective drug authorities,” added Hukare.

Related Posts

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform